Update Breast Cancer 2022 Part 2 - Advanced Stage Breast Cancer

Volkmar Müller, Manfred Welslau, Diana Lüftner, Florian Schütz, Elmar Stickeler, Peter A Fasching, Wolfgang Janni, Christoph Thomssen, Isabell Witzel, Tanja N Fehm, Erik Belleville, Simon Bader, Katharina Seitz, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Michael P Lux, Bahriye Aktas, Maggie Banys-PaluchowskiAndreas Schneeweiss, Nadia Harbeck, Rachel Würstlein, Andreas D Hartkopf, Hans-Christian Kolberg, Achim Wöckel


For patients with advanced breast cancer, several novel therapies have emerged in recent years, including CDK4/6 inhibitors, immune checkpoint inhibitors, PARP inhibitors, alpelisib, tucatinib and trastuzumab-deruxtecan, and sacituzumab-govitecan, which have transformed and expanded the therapeutic landscape for patients with advanced breast cancer. Some of these substances have now been approved for use in the early stages of the disease, or are expected to be approved in the near future, so the therapeutic landscape will change once again. Therefore, current scientific efforts are focused on the introduction of new substances and understanding their mechanisms of progression and efficacy. This review summarizes recent developments with reference to recent publications and conferences. Findings on the treatment of patients with HER2-positive breast cancer and brain metastases are presented, as are a number of studies looking at biomarkers in patients with HER2-negative, hormone receptor-positive breast cancer. In particular, the introduction of oral selective estrogen receptor degraders provides new opportunities to establish biomarker-based therapy. Molecular diagnostics is establishing itself as a diagnostic marker and parameter of progression.

Original languageEnglish
JournalGeburtshilfe und Frauenheilkunde
Issue number6
Pages (from-to)590-600
Number of pages11
Publication statusPublished - 06.2022

Research Areas and Centers

  • Centers: University Cancer Center Schleswig-Holstein (UCCSH)
  • Research Area: Luebeck Integrated Oncology Network (LION)


Dive into the research topics of 'Update Breast Cancer 2022 Part 2 - Advanced Stage Breast Cancer'. Together they form a unique fingerprint.

Cite this